Directorate Change

September 20, 2022
RNS Number : 9534Z
Renalytix PLC
20 September 2022

Renalytix plc

("Renalytix" or the "Company")


Renalytix Announces Change to Board of Directors


LONDON and SALT LAKE CITY, 20 September 2022 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that Ann Berman, non-executive director and chair of the audit and nomination committees, has resigned as a director of the Company for personal reasons effective immediately.


Ms. Berman commented, "I regret that I am unable to continue in my capacity as non-executive director of Renalytix, which for personal and family reasons, has become impractical. I remain highly encouraged by the Company's recent progress in reimbursement, regulatory and commercial milestones and believe KidneyIntelX holds the key to solving some of the intractable problems associated with patient suffering and cost related to diabetes and kidney disease."


Christopher Mills, chairman of the board of Renalytix, stated, "We are sorry that Ann will not to be able to continue with us as a director. Ann was a wonderful board member, and we extend our best wishes to her and her family."


The Company has begun a process to appoint a non-executive director and committee chair successors. 


The Board and the executive team would like to thank Ann for her dedication and contribution to the Company during her time as a non-executive director.



For further information, please contact:


Renalytix plc

James McCullough, CEO

Via Walbrook PR


Stifel (Nominated Adviser, Joint Broker)

Tel: 020 7710 7600

Alex PriceNicholas Moore



Investec Bank plc (Joint Broker)

Tel: 020 7597 4000

Gary Clarence / Daniel Adams


Walbrook PR Limited

Tel: 020 7933 8780 or

Paul McManus / Lianne Applegarth / Alice Woodings

Mob: 07980 541 893 / 07584 391 303 / 07407 804 654

CapComm Partners

Tel: 415-389-6400 or

Peter DeNardo



About Renalytix

Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The Company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company's lead product, KidneyIntelX™, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit For more information, visit


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.